M&A Comments Halozyme Therapeutics (HALO) shares edged 0.5% higher Wednesday morning after it raised its financial outlook and announced the acquisition of biopharmaceutical company Surf Bio for a total consideration of up to $400M ($300M upfront and up to $100M Post navigation Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 CongressREGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
M&A Comments Halozyme Therapeutics (HALO) shares edged 0.5% higher Wednesday morning after it raised its financial outlook and announced the acquisition of biopharmaceutical company Surf Bio for a total consideration of up to $400M ($300M upfront and up to $100M
